Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This study has been withdrawn prior to enrollment.
(Gallium is no longer available for the conduct of this study.)
Genta Incorporated
Information provided by (Responsible Party):
Scott E Smith, MD, PhD, Loyola University Identifier:
First received: February 3, 2009
Last updated: March 14, 2016
Last verified: March 2016
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: May 2012
  Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)